Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format. The percentage of full and empty capsids in an AAV drug product can significantly affect therapeutic benefit vs immunogenicity risk. Many challenges persist in viral vector manufacturing that can result in the gene of interest not being appropriately packaged in the capsid and therefore not delivered to the patient.
